IT Mac 400mg Tablet SR contains Itraconazole, a broad-spectrum triazole antifungal agent used for the treatment of various systemic and superficial fungal infections. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and improving patient compliance by reducing dosing frequency. Itraconazole acts by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. IT Mac 400mg Tablet SR is indicated for the treatment of infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other dermatophytic infections. It is also employed in the management of oropharyngeal and esophageal candidiasis, as well as prophylaxis in immunocompromised patients at risk of fungal infections. The sustained-release formulation allows for once-daily dosing, improving adherence in long-term therapy. Caution is advised in patients with hepatic impairment, congestive heart failure, or those receiving concomitant medications metabolized by CYP3A4 due to potential drug interactions. Regular monitoring of liver function tests is recommended during therapy. IT Mac 400mg Tablet SR should be used under medical supervision to ensure optimal therapeutic outcomes and minimize adverse effects.